Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles-Adjuvanted Vaccine Elicits Elevated Protective Responses In The Lung

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2019 Oct 22

PMID 31632026

Citations 10

Authors

Yumeng Li

Chuan Wang

Zhenjie Sun

Jian Xiao

Xiaoliang Yan

Yuqing Chen

Jian Yu

Yimou Wu

Affiliations

Soon will be listed here.

Abstract

Background: is a zoonotic bacteria closely associated with psittacosis/ornithosis. Vaccination has been recognized as the best way to inhibit the spread of due to the majority ignored of infections. The optimal vaccine was obstructed by the defect of single immunization route and the lack of availability of nontoxic and valid adjuvants.

Methods: In this study, we developed a novel immunization strategy, simultaneous (SIM) intramuscular (IM) and intranasal (IN) administration of a antigens (Ags) adjuvanted with chitosan nanoparticles (CNPs). And SIM-CNPs-Ags were used to determine the different types of immune response and the protective role in vivo.

Results: CNPs-Ags with zeta-potential values of 13.12 mV and of 276.1 nm showed excellent stability and optimal size for crossing the mucosal barrier with high 71.7% encapsulation efficiency. SIM-CPN-Ags mediated stronger humoral and mucosal responses by producing meaningfully high levels of IgG and secretory IgA (sIgA) antibodies. The SIM route also led to Ags-specific T-cell responses and increased IFN-γ, IL-2, TNF-α and IL-17A in the splenocyte supernatants. Following respiratory infection with , we found that SIM immunization remarkably reduced bacterial load and the degree of inflammation in the infected lungs and made for a lower level of IFN-γ, TNF-α and IL-6. Furthermore, SIM vaccination with CNPs-Ags had obviously inhibited disseminating to various organs in vivo.

Conclusion: SIM immunization with CNPs-adjuvanted Ags may present a novel strategy for the development of a vaccine against the infection.

Citing Articles

mRNA Galsomes Vaccine Protects Budgerigars Against Virulent Challenge.

De Meyst A, Van Mieghem J, Chiers K, Raemdonck K, Verbeke R, Lentacker I Vaccines (Basel). 2025; 13(2).

PMID: 40006752 PMC: 11861616. DOI: 10.3390/vaccines13020206.

Profile of vaccine research: A bibliometric analysis.

Wang X, Wang Q, Gao Y, Jiang L, Tang L Hum Vaccin Immunother. 2025; 21(1):2459459.

PMID: 39906958 PMC: 11801346. DOI: 10.1080/21645515.2025.2459459.

Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.

Gawad W, Nagy Y, Samir T, Mansour A, Helmy O NPJ Vaccines. 2025; 10(1):22.

PMID: 39893156 PMC: 11787396. DOI: 10.1038/s41541-025-01074-4.

Review of Intranasal Active Pharmaceutical Ingredient Delivery Systems.

Safarov R, Fedotova O, Uvarova A, Gordienko M, Menshutina N Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338342 PMC: 11435088. DOI: 10.3390/ph17091180.

Chitosan Nanoparticles for Intranasal Drug Delivery.

Omidian H, Gill E, Chowdhury S, Cubeddu L Pharmaceutics. 2024; 16(6).

PMID: 38931868 PMC: 11206675. DOI: 10.3390/pharmaceutics16060746.

References

Knittler M, Berndt A, Bocker S, Dutow P, Hanel F, Heuer D . Chlamydia psittaci: new insights into genomic diversity, clinical pathology, host-pathogen interaction and anti-bacterial immunity. Int J Med Microbiol. 2014; 304(7):877-93. DOI: 10.1016/j.ijmm.2014.06.010. View

Khan S, Polkinghorne A, Waugh C, Hanger J, Loader J, Beagley K . Humoral immune responses in koalas (Phascolarctos cinereus) either naturally infected with Chlamydia pecorum or following administration of a recombinant chlamydial major outer membrane protein vaccine. Vaccine. 2016; 34(6):775-82. DOI: 10.1016/j.vaccine.2015.12.050. View

Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R . Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomedicine. 2018; 13:7959-7970. PMC: 6260144. DOI: 10.2147/IJN.S165876. View

Dhakal S, Renu S, Ghimire S, Lakshmanappa Y, Hogshead B, Feliciano-Ruiz N . Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs. Front Immunol. 2018; 9:934. PMC: 5940749. DOI: 10.3389/fimmu.2018.00934. View

Bode J, Dutow P, Sommer K, Janik K, Glage S, Tummler B . A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci. PLoS One. 2012; 7(11):e50327. PMC: 3506576. DOI: 10.1371/journal.pone.0050327. View

Christensen D, Mortensen R, Rosenkrands I, Dietrich J, Andersen P . Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 2016; 10(1):260-270. DOI: 10.1038/mi.2016.28. View

Longbottom D, Livingstone M . Vaccination against chlamydial infections of man and animals. Vet J. 2006; 171(2):263-75. DOI: 10.1016/j.tvjl.2004.09.006. View

Frank L, Sandri G, DAutilia F, Contri R, Bonferoni M, Caramella C . Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery. Int J Nanomedicine. 2014; 9:3151-61. PMC: 4085301. DOI: 10.2147/IJN.S62599. View

Karunakaran K, Yu H, Foster L, Brunham R . Development of a Chlamydia trachomatis T cell Vaccine. Hum Vaccin. 2010; 6(8):676-80. PMC: 3056063. DOI: 10.4161/hv.6.8.12299. View

10.

van der Lubben I, Verhoef J, Borchard G, Junginger H . Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 2001; 52(2):139-44. DOI: 10.1016/s0169-409x(01)00197-1. View

11.

Beeckman D, Vanrompay D . Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol Infect. 2009; 15(1):11-7. DOI: 10.1111/j.1469-0691.2008.02669.x. View

12.

Pickering H, Teng A, Faal N, Joof H, Makalo P, Cassama E . Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection. Sci Rep. 2017; 7(1):9634. PMC: 5575166. DOI: 10.1038/s41598-017-09193-2. View

13.

Zheng K, Xu M, Xiao Y, Luo H, Xie Y, Yu J . Immunogenicity and protective efficacy against Treponema pallidum in New Zealand rabbits immunized with plasmid DNA encoding flagellin. Emerg Microbes Infect. 2018; 7(1):177. PMC: 6220273. DOI: 10.1038/s41426-018-0176-0. View

14.

Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol. 2002; 1(2):135-45. DOI: 10.1038/35100529. View

15.

Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza L . Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine. 2010; 28(48):7659-66. PMC: 2981640. DOI: 10.1016/j.vaccine.2010.09.040. View

16.

Chu J, Zhang Q, Zhang T, Han E, Zhao P, Khan A . Chlamydia psittaci infection increases mortality of avian influenza virus H9N2 by suppressing host immune response. Sci Rep. 2016; 6:29421. PMC: 4941526. DOI: 10.1038/srep29421. View

17.

van Drunen Littel-van den Hurk S, Gerdts V, Loehr B, Pontarollo R, Rankin R, Uwiera R . Recent advances in the use of DNA vaccines for the treatment of diseases of farmed animals. Adv Drug Deliv Rev. 2000; 43(1):13-28. DOI: 10.1016/s0169-409x(00)00074-0. View

18.

Zariwala M, Bendre H, Markiv A, Farnaud S, Renshaw D, Taylor K . Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery. Int J Nanomedicine. 2018; 13:5837-5848. PMC: 6166747. DOI: 10.2147/IJN.S166901. View

19.

da Silva R, da Silva J, Junior A, Marinho P, Santos L, Martins Teixeira F . Adsorption of Vi Capsular Antigen of Typhi in Chitosan-Poly (Methacrylic Acid) Nanoparticles. Polymers (Basel). 2019; 11(7). PMC: 6680519. DOI: 10.3390/polym11071226. View

20.

Sun T, Zhan B, Zhang W, Qin D, Xia G, Zhang H . Carboxymethyl chitosan nanoparticles loaded with bioactive peptide OH-CATH30 benefit nonscar wound healing. Int J Nanomedicine. 2018; 13:5771-5786. PMC: 6165789. DOI: 10.2147/IJN.S156206. View